Vysis' PathVysion Likely Challenger As Dako's HercepTest Enters Market
This article was originally published in The Gray Sheet
Executive Summary
If Vysis' presentation to FDA's Nov. 9 Immunology Devices Panel serves as any indication, the company's pending commercial introduction of the PathVysion HER-2 DNA Probe Kit will be aimed specifically at taking market share from Dako's HercepTest (see related story, p. 13).